United Therapeutics logo

United Therapeutics share price today

(UTHR)

United Therapeutics share price is $362.16 & -₹362.16 as on 12 Dec 2024, 2.30 'hrs' IST

$362.16

-0.08

(-0.02%)

Market is closed - opens 8 PM, 12 Dec 2024

View live United Therapeutics share price in Dollar and Rupees. Guide to invest in United Therapeutics from India. Also see the sentimental analysis on Indian investors investing in United Therapeutics. Get details on the Indian mutual funds that are investing in United Therapeutics. Get Analyst recommendations and forecasts along with all the United Therapeutics's financials.

United Therapeutics share price movements

  • $360.59
    $366.07

    Day's Volatility :1.5%

  • $208.62
    $417.82

    52 Weeks Volatility :50.07%

United Therapeutics Returns

PeriodUnited Therapeutics CorporationSector (Health Care)Index (Russel 2000)
3 Months
6.17%
-8.8%
0.0%
6 Months
25.93%
-2.7%
0.0%
1 Year
40.95%
6.5%
0.0%
3 Years
89.4%
5.6%
-20.0%

United Therapeutics Key Statistics

in dollars & INR

Previous Close
$362.24
Open
$363.51
Today's High
$366.07
Today's Low
$360.5939
Market Capitalization
$16.2B
Today's Volume
$250.5K
52 Week High
$417.815
52 Week Low
$208.6249
Revenue TTM
$2.8B
EBITDA
$1.4B
Earnings Per Share (EPS)
$22.75
PE Ratio
15.92
Profit Margin
40.31%
Quarterly Earnings Growth YOY
0.19%
Return On Equity TTM
18.81%

How to invest in United Therapeutics from India?

It is very easy for Indian residents to invest directly in United Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the United Therapeutics stock in both rupees (INR) and dollars (USD). Search for United Therapeutics or UTHR on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of United Therapeutics or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of United Therapeutics shares which would translate to -0.000 fractional shares of United Therapeutics as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards United Therapeutics

-77%

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Search volume for United Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 12, 2024. -77% less investors are searching United Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in United Therapeutics

  • BlackRock Inc

    12.25%

  • Vanguard Group Inc

    9.88%

  • Wellington Management Company LLP

    7.10%

  • venBio Select Advisor LLC

    6.40%

  • State Street Corp

    5.01%

  • Renaissance Technologies Corp

    4.83%

Analyst Recommendation on United Therapeutics

Buy

    81%Buy

    13%Hold

    4%Sell

Based on 22 Wall street analysts offering stock ratings for United Therapeutics(by analysts ranked 0 to 5 stars)

Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
17
Hold
3
3
2
Sell
1
1
2

Analyst Forecast on United Therapeutics

What analysts predicted

Upside of 5.54%

Current:

$362.16

Target:

$382.22

Insights on United Therapeutics

  • Price Movement

    In the last 3 years, UTHR stock has moved up by 92.1%
  • Increasing Revenue

    Revenue is up for the last 8 quarters, 491.5M → 748.9M (in $), with an average increase of 5.7% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 278.1M → 309.1M (in $), with an average increase of 10.0% per quarter
  • UTHR vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 46.2% return, outperforming this stock by 2.3%
  • Price to Sales

    ForUTHR every $1 of sales, investors are willing to pay $6.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $15.4 for every $1 of sales.

United Therapeutics Financials in INR & Dollars

FY18Y/Y Change
Revenue
$1.6B
↓ 5.65%
Net Income
$589.2M
↑ 40.99%
Net Profit Margin
36.2%
↑ 11.98%
FY19Y/Y Change
Revenue
$1.4B
↓ 11.0%
Net Income
$-104.5M
↓ 117.74%
Net Profit Margin
-7.21%
↓ 43.41%
FY20Y/Y Change
Revenue
$1.5B
↑ 2.38%
Net Income
$514.8M
↓ 592.63%
Net Profit Margin
34.71%
↑ 41.92%
FY21Y/Y Change
Revenue
$1.7B
↑ 13.63%
Net Income
$475.8M
↓ 7.58%
Net Profit Margin
28.23%
↓ 6.48%
FY22Y/Y Change
Revenue
$1.9B
↑ 14.88%
Net Income
$727.3M
↑ 52.86%
Net Profit Margin
37.56%
↑ 9.33%
FY23Y/Y Change
Revenue
$2.3B
↑ 20.2%
Net Income
$984.8M
↑ 35.4%
Net Profit Margin
42.31%
↑ 4.75%
Q2 FY23Q/Q Change
Revenue
$596.5M
↑ 17.68%
Net Income
$259.2M
↑ 7.6%
Net Profit Margin
43.45%
↓ 4.07%
Q3 FY23Q/Q Change
Revenue
$609.4M
↑ 2.16%
Net Income
$267.6M
↑ 3.24%
Net Profit Margin
43.91%
↑ 0.46%
Q4 FY23Q/Q Change
Revenue
$614.7M
↑ 0.87%
Net Income
$217.1M
↓ 18.87%
Net Profit Margin
35.32%
↓ 8.59%
Q1 FY24Q/Q Change
Revenue
$677.7M
↑ 10.25%
Net Income
$306.6M
↑ 41.23%
Net Profit Margin
45.24%
↑ 9.92%
Q2 FY24Q/Q Change
Revenue
$714.9M
↑ 5.49%
Net Income
$278.1M
↓ 9.3%
Net Profit Margin
38.9%
↓ 6.34%
Q3 FY24Q/Q Change
Revenue
$748.9M
↑ 4.76%
Net Income
$309.1M
↑ 11.15%
Net Profit Margin
41.27%
↑ 2.37%
FY18Y/Y Change
Total Assets
$3.4B
↑ 18.11%
Total Liabilities
$612.4M
↓ 21.24%
FY19Y/Y Change
Total Assets
$3.9B
↑ 15.07%
Total Liabilities
$1.1B
↑ 85.01%
FY20Y/Y Change
Total Assets
$4.6B
↑ 17.93%
Total Liabilities
$1.2B
↑ 7.66%
FY21Y/Y Change
Total Assets
$5.2B
↑ 12.01%
Total Liabilities
$1.2B
↓ 0.79%
FY22Y/Y Change
Total Assets
$6.0B
↑ 16.94%
Total Liabilities
$1.2B
↑ 3.11%
FY23Y/Y Change
Total Assets
$7.2B
↑ 18.57%
Total Liabilities
$1.2B
↓ 5.26%
Q2 FY23Q/Q Change
Total Assets
$6.7B
↑ 5.28%
Total Liabilities
$1.3B
↑ 3.88%
Q3 FY23Q/Q Change
Total Assets
$7.0B
↑ 5.12%
Total Liabilities
$1.3B
↑ 3.24%
Q4 FY23Q/Q Change
Total Assets
$7.2B
↑ 2.04%
Total Liabilities
$1.2B
↓ 9.86%
Q1 FY24Q/Q Change
Total Assets
$6.5B
↓ 9.37%
Total Liabilities
$1.2B
↓ 2.12%
Q2 FY24Q/Q Change
Total Assets
$6.7B
↑ 3.51%
Total Liabilities
$1.0B
↓ 11.33%
Q3 FY24Q/Q Change
Total Assets
$7.1B
↑ 5.95%
Total Liabilities
$1.0B
↓ 0.37%
FY18Y/Y Change
Operating Cash Flow
$778.4M
↑ 64.15%
Investing Cash Flow
$-820.6M
↓ 1.8%
Financing Cash Flow
$6.3M
↓ 85.45%
FY19Y/Y Change
Operating Cash Flow
$-206.6M
↓ 126.54%
Investing Cash Flow
$-335.4M
↓ 59.13%
Financing Cash Flow
$611.2M
↑ 9601.59%
FY20Y/Y Change
Operating Cash Flow
$755.7M
↓ 465.78%
Investing Cash Flow
$-738.5M
↑ 120.18%
Financing Cash Flow
$-16.9M
↓ 102.77%
FY21Y/Y Change
Operating Cash Flow
$598.2M
↓ 20.84%
Investing Cash Flow
$-486.9M
↓ 34.07%
Financing Cash Flow
$44.8M
↓ 365.09%
FY22Y/Y Change
Operating Cash Flow
$802.5M
↑ 34.15%
Investing Cash Flow
$-811.5M
↑ 66.67%
Financing Cash Flow
$75.4M
↑ 68.3%
Q2 FY23Q/Q Change
Operating Cash Flow
$106.3M
↓ 71.64%
Investing Cash Flow
$-227.2M
↑ 2.76%
Financing Cash Flow
$24.7M
↓ 49.18%

United Therapeutics Technicals Summary

Sell

Neutral

Buy

United Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

United Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
United Therapeutics Corporation
-9.66%
25.93%
40.95%
89.4%
103.67%
Regeneron Pharmaceuticals, Inc.
-5.85%
-24.7%
-11.77%
17.09%
105.58%
Biontech Se
12.25%
24.31%
22.8%
-57.11%
240.97%
Alnylam Pharmaceuticals, Inc.
-5.5%
58.79%
40.79%
36.33%
111.58%
Vertex Pharmaceuticals Incorporated
-4.43%
-2.24%
15.61%
124.98%
113.34%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
United Therapeutics Corporation
15.92
15.92
1.56
24.51
0.19
0.12
NA
136.74
Regeneron Pharmaceuticals, Inc.
19.27
19.27
1.17
45.03
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.24
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
United Therapeutics Corporation
Buy
$16.2B
103.67%
15.92
40.31%
Regeneron Pharmaceuticals, Inc.
Buy
$86.6B
105.58%
19.27
33.61%
Biontech Se
Buy
$28.0B
240.97%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$33.0B
111.58%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$122.1B
113.34%
32.84
-4.51%

About United Therapeutics

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
Organization
United Therapeutics
Employees
1168
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Industry
Health Technology

Management People of United Therapeutics

NameTitle
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Founder, Chairman & CEO
Mr. Michael I. Benkowitz
President & COO
Mr. James C. Edgemond
CFO & Treasurer
Mr. Paul A. Mahon J.D.
Executive VP, General Counsel & Corporate Secretary
Mr. Dewey Steadman C.F.A.
Head of Investor Relations
Ms. Holly Hobson
Associate Vice President of Human Resources
Kevin T. Gray
Senior Vice President of Strategic Operations & Logistics
Mr. Patrick Poisson
Executive VP of Technical Operations
Dr. Leigh Peterson
Executive Vice President of Product Development & Xenotransplantation
Mr. Gil Golden
Senior VP & Chief Medical Officer

Important FAQs about investing in United Therapeutics from India :

What is United Therapeutics share price today?

United Therapeutics (UTHR) share price today is $362.16.

Can Indians buy United Therapeutics shares?

Yes, Indians can invest in the United Therapeutics (UTHR) from India.

With INDmoney, you can buy United Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy United Therapeutics at zero transaction cost.

How can I buy United Therapeutics shares from India?

It is very easy to buy United Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of United Therapeutics be purchased?

Yes, you can buy fractional shares of United Therapeutics with INDmoney app.

What are the documents required to start investing in United Therapeutics stocks?

To start investing in United Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of United Therapeutics

Today’s highest price of United Therapeutics (UTHR) is $366.07.

Today’s lowest price of United Therapeutics (UTHR) is $360.59.

What is today's market capitalisation of United Therapeutics

Today's market capitalisation of United Therapeutics UTHR is 16.2B

What is the 52 Week High and Low Range of United Therapeutics

  • 52 Week High

    $417.82

  • 52 Week Low

    $208.62

How much percentage United Therapeutics is down from its 52 Week High?

United Therapeutics (UTHR) share price is $362.16. It is down by 13.32% from its 52 Week High price of $417.82.

How much percentage United Therapeutics is up from its 52 Week low?

United Therapeutics (UTHR) share price is $362.16. It is up by 73.59% from its 52 Week Low price of $208.62.

What are the historical returns of United Therapeutics?

  • 1 Month Returns

    -9.66%

  • 3 Months Returns

    25.93%

  • 1 Year Returns

    40.95%

  • 5 Years Returns

    103.67%

Who is the Chief Executive Officer (CEO) of United Therapeutics

Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. is the current Chief Executive Officer (CEO) of United Therapeutics.